Amazfit Expands Active 2 Lineup with the New Active 2 Square — All the Same Features, Now in a Sleek Square Design
MILPITAS, Calif.--(BUSINESS WIRE)--Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), a health technology company, today announced the launch of the square version of the Amazfit Active 2, a new addition to its fitness smartwatch line that offers the same powerful features and premium experience as the recently launched round Active 2 — now in a modern, square form factor.
Featuring a square, 1.75 inch sapphire glass high-definition AMOLED display elegantly encased in a polished stainless-steel frame.
Share
Same Features. New Shape.
Debuting at CES 2025 and featured at Pepcom and ShowStoppers, the Active 2 Square is designed for consumers who prefer a bold, geometric aesthetic without compromising performance, durability, or advanced health and fitness tracking.
Featuring a square, 1.75 inch sapphire glass high-definition AMOLED display elegantly encased in a polished stainless-steel frame, the Amazfit Active 2 delivers an optimal visual experience with a peak brightness of 2,000 nits, ensuring clarity even in bright light.
The graceful metal finish adds a sophisticated touch, perfectly complementing modern, style-conscious lifestyles. Its distinctive geometric form reflects a unique design identity and its intuitive interface and expansive viewing surface provide seamless access to health metrics, messages, and workouts. The device retains the full suite of features that made the round Active 2 a standout.
Product Specs
Latest Generation Biosensor: The BioTracker™ 6.0 PPG biosensor features a dual-LED and 5PD build, which picks up more biometric signals for enhanced precision in health monitoring and measurement.
Upgraded Heart Rate and Sleep Algorithms: The PulsePrecision™ algorithm enhances heart rate tracking accuracy to the level of the Amazfit T-Rex 3, while the RestoreIQ™ algorithm gives sleep monitoring a similar accuracy boost.
Additional Sensors: Compared to the previous generation of Amazfit Active, the new release adds a barometer for accurate altitude measurements and support of new sports like skiing, along with an accelerometer and gyroscope for precise recognition of sleep and movement, and an ambient light sensor for optimal display under varying light conditions.
Extended Battery Life: With a robust 10-day battery life under typical use, the Active 2 Square is a device that won't need recharging every night.
Zepp Flow™: Enables users to control their watch settings, adjust their calendar, and more with just their voice, while also granting Android users the ability to reply to instant messages with either keyboard or speech-to-text input.
Fitness and Wellness Features
Dynamic Fitness Modes: Over 160 sports modes including official HYROX Race Mode, a smart Strength Training mode that can auto-detect specific exercises and intelligently count reps, sets, and rest time, and new winter sports like Skiing.
Offline Maps with Turn Directions: Supported by 5 satellite systems, users can navigate with ease by importing offline maps and route files to the watch that come with turn-by-turn directions, which can be followed on-screen or broadcast via the built-in speaker or the user's connected Bluetooth headphones.
Zepp Coach™ Integration: Offers personalized training and running plans, empowering users of all levels to achieve fitness milestones from 3K runs to full marathons.
Tailored for Women: With the Wild.AI mini app, women can connect to their accounts directly from the watch for personalized wellness insights tied to their menstrual and hormonal cycles.
Advanced Health Insights: A daily Readiness score summarizes mental and physical recovery and provides actionable insights, while the HRV feature delivers specialized recovery data.
Availability and Pricing
The Amazfit Active 2 Square is available for purchase beginning today on Amazfit.com and Amazon. Priced at $149.99 USD or €149.90 euro, the Active 2 Square delivers premium features and performance at an unbeatable value.
For more information, please visit https://www.amazfit.com/en/ and follow us on Facebook, Instagram, X (formerly Twitter) and YouTube.
About Amazfit
Amazfit, a leading global smart wearable brand focused on health and fitness, is part of Zepp Health (NYSE: ZEPP), a health technology company with its principal office based in Gorinchem, the Netherlands. Zepp Health operates as a distributed organization, with team members and offices across the Americas, Europe, Asia, and other global markets.
Offering a wide selection of smartwatches and bands, Amazfit's brand tagline, 'Discover Amazing,' encourages individuals to break barriers, exceed expectations, and find joy in every moment. Amazfit is powered by Zepp Health's proprietary health management platform, which delivers cloud-based, 24/7 actionable insights and guidance to help users achieve their wellness goals.
Known for outstanding craftsmanship, Amazfit smartwatches have won numerous design awards, including the iF Design Award and the Red Dot Design Award. Launched in 2015, Amazfit is embraced by millions of users, with products available in over 90 countries across the Americas, EMEA, and APAC regions. For more information, visit www.amazfit.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
NFC Forum Announces NFC Release 15
LONDON--(BUSINESS WIRE)-- NFC Forum, the global standards body for Near Field Communication (NFC) technology, has announced NFC Release 15, supporting the latest advancements in NFC Forum-certified technologies. NFC Release 15 will extend the range of certified compliant NFC contactless connections up to 2cm – 4x greater than the current range of 0.5cm, supporting faster, more reliable contactless interactions across a growing number of use cases such as wireless charging, kitchen appliances, wearables, and digital keys. This innovation means that connections will start sooner and require less precise device alignment, making NFC quicker, more reliable, and easier to use than ever. Led by its Board members, including representatives from Apple, Google, Huawei, Identiv, Infineon, NXP, Sony, and ST Microelectronics, NFC Forum empowers organizations to deliver seamless, secure contactless interactions to users around the globe, with conformance to the Forum's specifications helping to ensure intuitive, reliable and consistent experiences. NFC Release 15 will extend the range – also known as the operating volume – of NFC contactless interactions. This innovation means that connections will start sooner and require less precise device alignment, making NFC quicker, more reliable and easier to use than ever. Contactless connections will be more seamless, while retaining the critical need for user intent. 'Extending the range of NFC contactless connections was one of the key priorities outlined in the NFC Forum Five-Year Roadmap, to meet changing market needs and deliver faster, easier transactions across all NFC enabled devices – including smaller form factors such as wearables or smartphones,' comments Mike McCamon, Executive Director of NFC Forum. 'Many markets are set to benefit from extended range, with consumers set to gain the most through an enhanced user experience. Redefining the baseline for contactless connections, NFC Release 15 is also expected to advance new and exciting use cases, such as using your mobile phone as a payment terminal, as well as optimize NFC usability across a variety of sectors, including automotive, transit and access control.' NFC Release 15 also marks the latest step in NFC Forum's ongoing commitment to sustainability, as one of its other core focuses is support for the NFC Digital Product Passport Standard. The standard gives brand and product teams a flexible, data agnostic framework to allow a single NFC tag embedded in a product to store and transmit both standard and extended DPP data using common NFC Data Exchange Format (NDEF) records. NFC Release 15 will therefore help to ensure reliability, interoperability, and compatibility across all NFC devices used for the DPP, throughout a product's entire lifecycle. 'NFC technology makes our lives more convenient, secure and connected every single day. NFC Release 15 will continue to extend contactless simplicity into an ever-expanding list of use cases – including sustainability – and redefine the baseline for performance standards,' continues McCamon. 'NFC Forum is committed to helping organizations deliver secure, reliable and convenient proximity-based connections, driven by user intent. Through NFC Release 15, we are proud to enable these NFC interactions as the technology, its applications and ability to drive a more connected, sustainable future show no signs of slowing.' NFC Forum Associate, Principal, and Sponsor-level member companies can download the Technical Specifications included in NFC Release 15 today. Adopter-level members and the public can access and begin certifying compliance to NFC Release 15 from Fall 2025. To learn more about NFC Release 15 and how it will enable extended range, the circular economy and expansion of use cases, register to attend our upcoming webinar on Wednesday 9 th July. About the NFC Forum The NFC Forum, established in 2004, is a non-profit industry association comprised of leading mobile communications, semiconductor, and consumer electronics companies. Its mission is to advance the use of Near Field Communication technology by developing specifications, ensuring interoperability, and educating the market about NFC technology. The NFC Forum's global member companies share skills, technical expertise and industry knowledge to develop specifications and protocols for interoperable data exchange, device-independent service delivery, and device capability. Forum's supporting certification program and user marks enhance and promote a consistent, reliable, seamless and secure NFC user experience. To learn more about joining the Forum, visit Follow the NFC Forum on LinkedIn and YouTube.
Business Wire
an hour ago
- Business Wire
Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)
BARCELONA, Spain--(BUSINESS WIRE)--Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development of progressive supranuclear palsy (PSP), has received Fast Track designation from the US Food & Drug Administration (FDA). FNP-223, a new molecular entity in active development for PSP, is in an ongoing Phase 2 study to evaluate its safety, efficacy, and pharmacokinetics in adult patients with possible or probable PSP-Richardson syndrome (PSP-RS), the most common clinical variant of this neurodegenerative disease 1. We are thrilled to receive Fast Track designation from the FDA for FNP-223 in the treatment of PSP. Consistent with our purpose of using business to fight for social justice, we are committed to advancing this promising therapy to patients. Share 'We are thrilled to receive Fast Track designation from the FDA for FNP-223 in the treatment of PSP. Consistent with our purpose of using business to fight for social justice, we are committed to advancing this promising therapy as quickly as possible to benefit as many patients as possible,' said Mario Rovirosa, Chief Executive Officer of Ferrer. Fast Track designation is a significant milestone in the drug development process. It is a program that offers the possibility of having more frequent meetings with the FDA to discuss the drug's development, eligibility for Accelerated Approval and Priority Review if relevant criteria are met. 'This designation underscores the importance of expediting the development and review of FNP-223 to address critical unmet needs in patients with this rare and devastating disease,' said Marta Parmar, Ferrer's Chief Quality, Regulatory and Pharmacovigilance Officer. Progressive supranuclear palsy manifests in patients with symptoms such as difficulty speaking, imbalance, changes in gait, cognitive problems 2-4. PSP has a prevalence of approximately 5 cases per 100,000 people and primarily affects individuals over the age of 60 3. The disease's etiology is believed to be related to the abnormal accumulation of tau proteins in certain areas of the brain, leading to neurodegeneration 3,4. Preclinical models have demonstrated that FNP-223 can prevent the abnormal accumulation of tau proteins in neurons 5. Ferrer now aims to show that this molecule is safe and effective in patients with PSP. Oscar Pérez, Chief Scientific Officer of Ferrer, also expressed his enthusiasm: "Receiving Fast Track designation is a significant milestone in our journey to provide a transformative treatment for PSP. We are excited to advance our research and hopefully offer a new therapeutic option earlier for patients living with this challenging condition." About FNP-223 FNP-223 is a new orally administered chemical compound that functions as a reversible and substrate-competitive inhibitor of the O-GlcNAcase (OGA) enzyme 5. Mechanistically, FNP-223 binds to the active site of OGA enzyme. As a result, the inhibitor prevents the substrate from accessing the catalytic pocket, thereby impeding the removal of O-GlcNAc modifications from natural client proteins such as the tau protein. Inhibiting O-GlcNAcase is expected to cause a rapid increase of O-GlcNAcylated (glycosylated) tau proteins, ultimately leading to a reduction in abnormal aggregated tau as neurofibrillary tangles (NFT) over a certain period 5. Bibliography: 1. A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER). [Internet]. Available from: 2. Coughlin DG, Litvan I. Progressive supranuclear palsy: Advances in diagnosis and management. Parkinsonism Relat Disord. 2020 Apr;73:105-116. doi: 10.1016/ Epub 2020 May 25. 3. Agarwal S, Gilbert R. Progressive Supranuclear Palsy. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: 4. Rowe JB, Holland N, Rittman T. Progressive supranuclear palsy: diagnosis and management. Pract Neurol. 2021;21(5):376-383. doi: 10.1136/practneurol-2020-002794. 5. Permanne B, Sand A, Ousson S, Nény M, Hantson J, Schubert R, et al. D. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies. ACS Chem Neurosci. 2022 Apr 20;13(8):1296-1314. doi: 10.1021/acschemneuro.2c00057.
Business Wire
an hour ago
- Business Wire
Mursla Bio Introduces AI Precision Medicine Platform Built on Organ-Specific EV Isolation from Blood
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve cancer outcomes for at-risk patients, today announced the commercial launch of its AI Precision Medicine Platform, alongside a pre-print¹ reporting the first validated method for isolating hepatocyte EVs from plasma for organ-specific proteomic and miRNA profiling. Mursla Bio is engaging with potential partners to apply its Platform to additional disease areas, biomarker discovery and IVD translation programs. The Platform addresses a major gap in liquid biopsy and precision medicine: enabling non-invasive access to organ-specific molecular information from blood with high spatial and biological resolution. Mursla Bio's Platform is built on its ability to isolate and analyze EVs which are secreted by specific organs into the bloodstream. The Platform reduces non-target background by up to five orders of magnitude compared to standard bulk EV isolation and significantly improves data structure, enhancing prediction model generalization. The pre-print presents the first multi-layered validation of hepatocyte EV isolation in humans, confirming liver origin through proteomic and nucleic acid markers. Key supporting proteomics data was generated in collaboration with Evotec International GmbH. Patient samples were provided by University College London, with Professor Brian Davidson, a global leader in liver disease surgery and clinical research, contributing as a co-author. The study shows that Mursla Bio's method yields robust, organ-specific multi-omics data using minimal blood volume, offering a novel scalable approach for biomarker and AI development. Mursla Bio's Platform incorporates optimized multi-omics workflows, embedded AI pipelines, and IVD translation processes to convert complex biological signals into practical, regulatory-grade assays. These assays are deployable on standard commercial instruments using patented, PCR and ELISA-like steps designed for clinical adoption. The Platform also underpins the development of EvoLiver™, the Company's lead clinical program for liver cancer surveillance in cirrhotic patients. Built on multi-omics data from over 300 patients, EvoLiver achieved 86% sensitivity and 88% specificity on a locked, IVD-compatible assay for early-stage hepatocellular carcinoma detection², and has received Breakthrough Device Designation from the FDA³. Pierre Arsène, Founder and CEO of Mursla Bio, said: "EVs are nature's native signal enrichment system for long-distance communication between cells and organs. Our platform harnesses this biology to non-invasively access organ-specific, multi-omics data from just a small blood sample. It produces structured, biologically labeled datasets that are optimized for AI and ready to support diagnostic translation. EvoLiver is our first proof point of real-world clinical impact, and we are now expanding access to the platform to advance our pipeline and enable partnerships across other disease areas.' Mursla Bio is expanding its pipeline and collaborations, with additional organ programs underway in cardiometabolic, lung, and neurological indications. The Platform will support pharma development through dynamic patient stratification, therapeutic response monitoring, surrogate markers and molecular phenotyping across complex disease biology. For further information on Mursla Bio's AI Precision Medicine Platform, please visit
